JPMorgan Chase & Co. Cuts Cooper Companies (NASDAQ:COO) Price Target to $71.00

Cooper Companies (NASDAQ:COO) had its target price dropped by stock analysts at JPMorgan Chase & Co. from $80.00 to $71.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 6.29% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC decreased their price objective on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a research report on Friday. Barclays boosted their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, March 6th. Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a research note on Friday. Finally, Citigroup reaffirmed a “neutral” rating and issued a $69.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $82.64.

Cooper Companies Stock Performance

NASDAQ COO traded up $4.78 during mid-day trading on Friday, reaching $66.80. 4,852,176 shares of the stock were exchanged, compared to its average volume of 2,251,741. The business’s 50 day moving average is $65.17 and its 200-day moving average is $74.57. Cooper Companies has a 1 year low of $58.89 and a 1 year high of $89.83. The company has a market capitalization of $13.03 billion, a P/E ratio of 32.94, a P/E/G ratio of 1.56 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.11. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.Cooper Companies’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period last year, the firm earned $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, equities research analysts forecast that Cooper Companies will post 4.62 EPS for the current fiscal year.

Institutional Trading of Cooper Companies

A number of hedge funds have recently modified their holdings of the business. Root Financial Partners LLC increased its position in shares of Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares in the last quarter. SJS Investment Consulting Inc. increased its holdings in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares in the last quarter. Bell Investment Advisors Inc boosted its stake in Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares in the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Cooper Companies during the second quarter worth $36,000. Finally, True Wealth Design LLC raised its holdings in shares of Cooper Companies by 484.8% in the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Fiscal Q2 results beat expectations, with revenue of $1.082 billion and non-GAAP EPS of $1.21, both above analyst forecasts. Revenue rose 8% year over year, signaling solid underlying demand across the business. Article Title
• Positive Sentiment: Management said it has reached agreements to resolve substantially all claims related to the embryo culture media recall, which reduces a major legal overhang and improves investor confidence in the company’s outlook. Article Title
• Positive Sentiment: Several analysts reiterated bullish views despite lowering price targets, including Needham and Baird, suggesting Wall Street still sees meaningful upside from current levels. Article Title
• Neutral Sentiment: Cooper Companies raised FY 2026 guidance, with non-GAAP EPS now expected at $4.58 to $4.66, roughly in line with consensus. That keeps expectations steady rather than dramatically changing the outlook. Article Title
• Negative Sentiment: GAAP EPS came in at a loss because of a $271.6 million litigation-related charge, and the stock was also affected by a broader market pullback as strong jobs data raised fears of more hawkish Federal Reserve policy. Article Title

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.